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KEY POINTS
 Medical therapy, as in the case of 5-aminosalicylic acid, may have mechanistic plausibility
for direct antineoplastic properties, but others, such as thiopurines, do not, suggesting
that there is a primary chemopreventive benefit derived from the ability to achieve endo-
scopic and histologic healing.
 Mucosal healing induced by medical therapy may also provide a secondary preventive
benefit by allowing improved endoscopic and histologic detection and differentiation be-
tween reactive epithelial changes and dysplasia.
 Of the many risk factors for the development of colitis-associated colorectal cancer
(CRC), one of the most modifiable for a treating physician is the presence and severity
of chronic inflammation.
 Although the mechanism of the declining risk of CRC in IBD is unclear, the likely determi-
nants are a combination of primary prevention resulting from improved medical therapies
able to induce mucosal healing, and secondary prevention derived from improved surveil-
lance endoscopy technologies.INTRODUCTION
Current goals of therapy for inflammatory bowel disease (IBD) are the induction and
maintenance of inflammatory symptoms to provide an improved quality of life, to
reduce the need for long-term corticosteroids, and to reduce other long-term
outcomes such as disability, hospitalization, and colorectal cancer (CRC).1 Although
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Chapman & Rubin354IBD-associated colorectal cancer (CRC) appears to have declined over the past
30 years.2 The observed decrease in CRC is thought to be due to a combination of fac-
tors, including improvements in the ability to identify and to quantify patients at risk and
to detect precancerous lesions, and the direct and indirect reduction in cancer result-
ing from effective medical and surgical therapies of the underlying inflammation.
Some of the well-defined genetic molecular pathways leading to sporadic or
hereditary CRC also appear to be present in colitis-associated CRC. However, IBD-
associated adenocarcinoma does not seem to follow the discrete adenoma-to-CRC
sequence of events.3 Rather, a progression, from inflamed mucosa to low-grade
dysplasia (LGD) to high-grade dysplasia (HGD) to invasive adenocarcinoma, in IBD re-
mains presumed and unproven. In fact, neoplasia in colitis takes different forms, a fact
that has resulted in difficulty classifying, identifying, and developing appropriate pre-
vention strategies for it. Cells from colonic mucosa in patients with chronic colitis have
the molecular fingerprints of dysplasia and cancer, including genomic instability
(aneuploidy), aberrant DNA methylation, and p53 mutations, even before there is
any histologic evidence of dysplasia or cancer.4 It is thought that such a “field effect”
of CRC risk is induced by chronic long-standing mucosal inflammation.
Most recently, the degree of inflammation has been shown to be a significant risk
factor for neoplasia in IBD.5,6 In addition to the presence and degree of severity of
active endoscopic/histologic colonic inflammation, additional established IBD-
associated dysplasia and CRC risk factors include extent and duration of disease,
family history of CRC, concomitant primary sclerosing cholangitis (PSC), young age
at diagnosis, and presence of postinflammatory polyps and strictures.4,6 Of these
risks, the only modifiable risk factor may be the degree of active inflammation. There-
fore, it has been proposed that effective disease control through abrogation of inflam-
mation may also reduce CRC risk in the individual patient.
Although the culmination of this evidence to date supports the clinician-adopted
theory that treating to achieve mucosal healing will reduce the risk of CRC in patients
with IBD, it remains uncertain how these recommendations can be practically applied
by clinicians trying to develop effective dysplasia and CRC prevention strategies in
IBD. This article summarizes the potential for medical therapy to reduce the risk of
CRC via primary and secondary prevention, and offers practical ways in which a
goal of mucosal improvement or healing may be incorporated into clinical practice
(Box 1).
DEFINITION OF REMISSION IN IBD: AN EVOLVING TARGET
The end point of escalation of therapy in IBD has traditionally been based on adequate
symptom control.7 Despite patient satisfaction in the achievement of clinicalBox 1
Mechanisms by which medical therapy may reduce colorectal cancer in IBD
Primary chemoprevention
Medical therapy reduces inflammation over time
Medical therapy has unique chemoprotection mechanisms
Secondary prevention
Treatment to achieve a healed bowel results in more accurate neoplasia detection by
endoscopy
Reduction in histologic inflammation improves pathologist’s diagnosis of neoplasia
Medical Therapy for Cancer Prevention in IBD 355remission, in many patients this goal is believed to be insufficient in achieving addi-
tional goals of stable remission over time and changing the natural history of the dis-
ease. In fact, multiple lines of investigation have demonstrated that a significant
proportion of IBD patients in clinical (symptomatic) remission continue to have active
mucosal inflammation, both endoscopically and histologically.8 In addition, a prospec-
tive study in patients with active colonic or ileocolonic Crohn’s disease treated with
steroids found no correlation between the clinical activity index and any of the endo-
scopic data, and although 92% of patients achieved clinical remission, less than one-
third of patients also achieved concomitant endoscopic remission.9
Clinically the achievement of a healed mucosa has been associated with a modified
course of IBD, including a reduction in rates of clinical relapse, fewer inpatient
hospitalizations, and decreased lifetime risk of surgery.10–12 Evidence that a healed
bowel mitigates the development of IBD-associated dysplasia and CRC has been
insufficient. With the increased interest in endoscopic mucosal healing in clinical
trials, it is hoped that additional evidence will demonstrate a direct link between
this end point and subsequent reduction in CRC risk. Clinical trials to date have varied
definitions ranging from endoscopic resolution of all mucosal ulcerations to endo-
scopic scoring indices, with very few studies evaluating histologic healing. Therefore,
a remaining challenge is this discrepancy between the clinical trials definition of
mucosal healing through endoscopic measures and the available evidence related
to risk for neoplasia in colitis, which is histologically measured. More recently, the
US Food and Drug Administration has expressed interest in histologic assessment
of bowel healing, which undoubtedly will lead to additional study and resource
allocation.
Nonetheless, as the bar is raised to achieve deeper levels of mucosal healing, one of
the significant challenges is the poor correlation between macroscopic mucosal heal-
ing as gauged by endoscopic assessment and endoscopist interpretation, and histo-
logically measured disease control as measured by biopsy sampling and pathologist
interpretation. In a study of 152 IBD patients in clinical remission undergoing routine
surveillance colonoscopy, Baars and colleagues8 found that only 67% of patients in
clinical remission had histologically active inflammation, and of these patients 50%
were endoscopically normal. Similarly, in a study of 82 asymptomatic patients with ul-
cerative colitis (UC), Rubin and colleagues identified that more than 30% of patients
had endoscopic inflammation and 89% had histologic evidence of active inflamma-
tion.13 If it is considered that a strict definition of mucosal healing should include res-
olution of histologic inflammation in addition to an endoscopic assessment of healing,
these studies demonstrate the real-world challenge to this approach and emphasize
the importance of further study.
A well-described challenge to the use of mucosal healing as a primary end point of
the treatment of IBD is the trade-off between risks and benefits (and costs) in patients
who feel well, but require escalation of therapy to achieve deeper levels of disease
control. It is unclear whether such additional disease control is possible, and whether
patients will be willing to escalate their therapy to achieve such control when they are
already in clinical remission. Will such dose or class escalation result in more adverse
events than benefits? Will it result, as the available evidence thus far suggests, in most
patients “burning” through all of the available therapies and never achieving this level
of inflammation control? How will the loss of this level of control and so-called disease
drift be monitored? How often, and how invasive will repeated assessments be
needed? Obviously there remain many unanswered questions before a disease-
wide modification in treatment goals can be applied. Nonetheless, there are ongoing
efforts to apply a treat-to-target approach used in other chronic diseases to IBD.14
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therapies.
TREATMENT TO MUCOSAL HEALING MAY IMPROVE DETECTION OF NEOPLASIA IN IBD
Being able to accurately detect precancerous lesions in patients with colonic IBD is
requisite for screening colonoscopy and subsequent interval surveillance examina-
tions. IBD-associated colorectal neoplasia may be a challenge to detect endoscopi-
cally because it may be multifocal, broadly infiltrating, and arising from flat mucosa,
and therefore endoscopically indistinct from the surrounding tissue. Therefore, to
adequately sample representative mucosa and identify dysplasia histologically, histor-
ical (and current) guidelines endorsed by multiple societies suggest 4-quadrant
random biopsy specimens obtained every 10 cm throughout the colon, aiming to
obtain at minimum 32 biopsy samples.15 However, this approach is limited in that it
samples less than 1% of colonic surface area and at the same time is subject to
poor patient compliance with surveillance, lack of gastroenterologist knowledge,
and compliant practice patterns, in addition to poor pathologist interobserver agree-
ment for dysplasia diagnoses.16,17
Furthermore, retrospective studies evaluating the visibility of dysplasia and CRC in
patients with IBD have found that most dysplastic lesions are endoscopically visible. In
a 14-year, retrospective review of 2204 surveillance colonoscopies, Rutter and col-
leagues18 found the neoplastic per-lesion and per-patient sensitivity to be 77.3%
and 89.3%, respectively. A total of 22.7% of lesions were macroscopically invisible
on colonoscopy. A 10-year, single-institution, retrospective study by Rubin and col-
leagues19 in the United States similarly found dysplasia or cancer had per-lesion
and per-patient endoscopic visibility of 61.3% and 76.1%, respectively. In this series,
38 of 65 dysplastic lesions (58.5%) and 8 of 10 cancers (80.0%) were visible to the
endoscopist as 23 polyps and masses, 1 stricture, and 22 areas of irregular mucosa.
In this series 38.7% of lesions were endoscopically invisible, detected only by random
biopsy. These retrospective studies did not account for the advent of newer advances
in colonoscopic technology, including high-definition or image-enhancement endos-
copy techniques such as chromoendoscopy, all of which are believed to further
improve visualization and guide future preventive approaches.
In the setting of macroscopically active inflammation, the pathologic diagnosis of
dysplasia is often more challenging, primarily because of the difficulty in differentiating
inflammation-associated regenerative changes and true dysplasia. In the setting of
healing UC, epithelial regeneration occurs with changes that may mimic dysplasia,
especially in the eyes of the less experienced pathologist. The epithelial cells become
cuboidal with eccentric, large nuclei, mucin depletion, and prominent nucleoli.20 As a
result, pathologists may need to interpret such biopsy specimens as “indefinite for
dysplasia” or undiagnosable for dysplasia. Therefore, in addition to the pursuit of
mucosal healing as a method of primary prevention of dysplasia and CRC, its achieve-
ment may also provide benefit in secondary prevention of CRC, defined as the
accurate detection of existing precancerous lesions by gastroenterologists and pa-
thologists. Completing a surveillance colonoscopy in the setting of mucosal healing
should improve visualization of neoplastic lesions for the endoscopist, and improve
the ability of pathologists to distinguish regenerative change from true dysplasia.
MEDICAL THERAPYAS PRIMARY CHEMOPREVENTION IN IBD-ASSOCIATED NEOPLASIA
The pathophysiology of colitis-associated dysplasia and cancer have implicated the
molecular products of chronic inflammation from both innate and adaptive immune
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associated neoplasia.21 This relationship is supported by the severity of histologic
inflammation as an independent risk factor for neoplastic progression.22,23 In addition
to directly reducing inflammation, medical therapy may play a primary chemopreven-
tive role, altering the molecular pathways to dysplasia development (Box 2).
5-Aminosalicylates
With demonstrated clinical efficacy and favorable safety profile, 5-aminosalicylic
acid (5-ASA) derivatives are the foundational first-line therapy for the induction and
maintenance of mild to moderate ulcerative colitis. In addition to the clinical benefit
of their anti-inflammatory mechanism, advances in understanding the mechanisms
of action reveal multiple molecular chemopreventive properties, including: promotion
of cell-cycle arrest to increase the stability of the genome and DNA replication fidelity;
inhibition of lipoxygenase and cyclooxygenase-2 (COX-2), thereby regulating angio-
genesis via prostaglandin synthesis; scavenging of free radicals and reactive oxygen
and nitrogen species to reduce DNA oxidative stress and microsatellite instability; and
induction of expression of peroxisome proliferator-activated receptor g (PPAR-g), a
potent tumor suppressor that interferes with canonical Wnt/b-catenin activity for pre-
vention of CRC.24–26
Since 5-ASA was first linked with a reduction in the risk of colitis-associated cancer
in 1994,27 there have been multiple retrospective cohort and case-control observa-
tional studies with differing results. In 2005, a systematic review and meta-analysis
of 9 observational studies and 1932 patients concluded that there was a protective as-
sociation between 5-ASA use and cancer (odds ratio [OR] 0.51; 95% confidence inter-
val [CI] 0.37–0.69), and between 5-ASA and cancer and dysplasia (OR 0.51; 95% CI
0.38–0.69).28 However, since that time, 5 and case-control studies with a larger pop-
ulation cohort have published data that are discordant, demonstrating no protective
association.29–33 The largest of these, using the Manitoba IBD epidemiology data-
base, found no protective benefit in those using 5-ASA therapy for 1 year or longer
and 5 years or longer based on a cohort of 8744 IBD patients (OR 1.04, 95% CI
0.67–1.62 and OR 2.01, 95% CI 1.04–3.9, respectively) and a case-control population
of 404 CRC patient (OR 1.02, 95% CI 0.60–1.74 and 1.96, 95% CI 0.84–4.55, respec-
tively).30 Similarly, in a more recent meta-analysis that focused on nonreferral studies
to reassess the role of 5-ASA for CRC protection, Nguyen and colleagues34 found no
protective benefit, with a pooled adjusted odds ratio of 0.95 (95% CI 0.66–1.38) and
moderate study heterogeneity (I2 5 58.2%; P 5 .07).
The clinical evidence is hindered by the inherent imperfections of an observational,
retrospective investigation, including patient heterogeneity in disease duration and
extent, study design and data sources, and monitoring compliance and concomitant
medical therapy. There is molecular mechanistic reasoning supporting the use of
5-ASA in colitis-associated cancer prevention, and although the clinical observational
studies to date have yielded discrepant results, the 2010 AmericanBox 2
Potential chemoprotective agents in IBD-associated dysplasia and colorectal cancer
5-Aminosalicylic acid
Thiopurine
Anti–tumor necrosis factor antibodies
Chapman & Rubin358Gastroenterological Association technical review favored, with moderate certainty,
that 5-ASA is chemopreventive against CRC.35 Although it remains a point of conten-
tion, the overall safety of these therapies has resulted in many clinicians continuing
their use even when other drugs are used for disease control, even if only because
of the possibility of such secondary benefit.
Thiopurines
Systemic immunomodulators including the traditional thiopurines, 6-mercaptopurine
(6-MP) and its nitroimidazole derivative, azathioprine (AZA), are purine synthesis inhib-
itors used in a primary and adjunctive role for the maintenance of remission in patients
with both Crohn’s disease and UC, in addition to the prevention of immunogenicity
against monoclonal antibody therapies, including anti–tumor necrosis factor (TNF)-a
and anti-integrin inhibitors. Whereas 5-ASA derivatives have biological mechanisms
of action rationalizing their potential role as chemopreventive agents, thiopurines’
lack of evidence demonstrating direct antineoplastic mechanisms to suggest any
benefit in reducing the risk of dysplasia or CRC may be due to their established
anti-inflammatory effects.
Initial studies evaluating the chemopreventive benefits of thiopurines had
discrepant results, with most demonstrating no benefit in chemoprevention (but
also no increased risk of cancer). In 2010, the available literature was insufficient
evidence for the American Gastroenterological Association to make recommenda-
tions for or against the use of thiopurines as potential chemopreventive agents.36
However, recent clinical studies have provided sufficient evidence to reconsider
the potential for 6-MP and AZA to reduce the risk of colitis-associated dysplasia
and CRC in patients with IBD.
Two large population-based cohorts, similar to prior studies, had different results. In
a Dutch cohort of 2578 patients with IBD, van Schaik and colleagues33 reported that
28 patients (1%) developed HGD or CRC during 16,289 person-years of follow-up.
Two of 28 patients (7%) were on thiopurines alone and 1 patient (of 28, 4%) was on
a thiopurine plus 5-ASA. Thiopurine use was associated with a significantly decreased
risk of developing HGD or CRC with an adjusted hazard ratio (HR) of 0.10 (95% CI
0.01–0.75). However, Pasternak and colleagues37 found no protective benefit in a
Danish cohort of 45,986 IBD patients, of which 11% were on AZA (adjusted relative
risk [RR] 5 1.00; 95% CI 0.61–1.63).
In 2013, the first prospective study of the epidemiology of colorectal HGD and can-
cer in IBD in the thiopurine era was published by Beaugerie and colleagues.38 The
results of the CESAME (Cancers Et Surrisque Associe´ aux Maladies Inflammatoires
Intestinales En France) trial, a French nationwide observational cohort of 19,486 pa-
tients with IBD designed in the early 2000s to assess the risks of any cancer or
HGD in IBD patients, found that 57 (0.3%) patients developed HGD or CRC during
the follow-up period (37 CRC, 20 colorectal HGD). In patients with long-standing,
extensive colitis, defined as disease duration of at least 10 years and extent of at least
50% of the colon, the multivariate adjusted HR for colorectal HGD and CRC was 0.28
for those who received thiopurines (95% CI 0.1–0.9; P 5 .03).
In the study of inflammation risk by Rubin and colleagues,5 multivariate analysis
identified thiopurine exposure as a significant predictive factor (adjusted OR 0.25;
95% CI 0.08–0.74). This finding, after controlling for degree of inflammation, was
one of the strongest lines of evidence to date.
A meta-analysis pooling of 19 studies (9 case-control and 10 cohort studies), while
acknowledging high heterogeneity among studies (I2 5 68.0%, P<.001), reported
that the use of thiopurine was associated with a statistically significant decreased
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0.94; P 5 .017), even after adjustment for duration and extent of the disease.39 In the
thiopurine-treated patients, the RR of HGD and CRC was 0.72 (95% CI 0.50–1.03;
P 5 .070) and 0.70 for CRC (95% CI 0.46–1.09; P 5 .111).
Despite these recently published reports demonstrating a reduced risk of dysplasia
and CRC with thiopurine use, any derived chemopreventive benefit is likely to remain
adjunctive to standard clinical indications for use. Given its known risk profile, lack of
plausible biological mechanism, success of surveillance colonoscopy, and, possibly,
increased anti-inflammatory benefit from anti–TNF-a antibodies, unlike 5-ASA thera-
pies, thiopurines are very unlikely to be recommended as a pure chemopreventive
agent in isolation.
Anti–TNF-a Antibodies
Anti-TNF agents are able to induce and maintain mucosal healing in the subset of pa-
tients with moderate to severe UC and Crohn’s disease, and as a result are likely
providing additional chemopreventive benefits by reducing long-standing chronic
inflammation. In addition, early investigations into the molecular mechanisms of
TNF-a in colitis have suggested a possible direct antineoplastic role from TNF
blockade. Using an in vivo dextran sulfate sodium (DSS) and azoxymethane mouse
model for chronic colitis–induced cancer, Popivanova and colleagues40 identified an
increase in the levels of TNF-a and infiltrating leukocyte TNF receptor in the colonic
mucosa and submucosa before the development of colonic tumors. Treating the
mice with a human TNF-a antagonist, etanercept, resulted in decreased tissue injury,
and low levels of inflammatory infiltrate and neutrophil-derived and macrophage-
derived chemokines. Tumors were reduced in number and size and had poor angio-
genesis, presumably from the suppressed COX-2 expression.
The few studies that evaluate the efficacy of anti-TNF agents to reduce the risk of
colitis-associated dysplasia and cancer have discordant findings. In a Dutch nation-
wide, nested case-control study of 173 cases of IBD-associated CRC from 1990 to
2006, the use of anti-TNF (OR 0.09, 95% CI 0.01–0.68; P 5 .02) was significantly pro-
tective for the development of CRC. However, in a nationwide population-based
Danish cohort, there was no significant difference in the risk of colitis-associated
CRC in IBD-exposed patients when compared with nonexposed patients (adjusted
RR 1.06; 95% CI 0.33–3.40).
Ursodeoxycholic Acid
Patients with a concomitant diagnosis of UC and PSC remain at a very high risk for
the development of dysplasia and CRC. Ursodeoxycholic acid (UDCA) is a syn-
thetic bile acid that has been proposed to have a molecular mechanism that can
reduce the risk of dysplasia and CRC by decreasing the colonic concentration of
bile acids, inhibiting Ras gene mutations and COX-2 expression, and having antiox-
idant activity. In a prospective, randomized, placebo-controlled trial of UDCA ther-
apy in 52 patients with UC and PSC, 10% of patients receiving UDCA developed
CRC versus 35% of patients not on UDCA therapy, resulting in a significant
RR of 0.26 for developing colorectal dysplasia or cancer (95% CI 0.06–0.92;
P 5 .034).41 However, this prospective study has been countered by several
studies reporting that long-term high-dose (28–30 mg/kg daily) UDCA is not protec-
tive in UC or PSC patients, and instead may increase the risk of colorectal
neoplasia.42 Therefore, at present the use of UDCA for chemoprotective reasons
alone is not recommended.
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With mucosal healing now entrenched as a clinical trial end point and significant
evidence demonstrating that mucosal healing modifies the course of the disease,
including potentially reducing the risk of cancer via primary and secondary prevention,
one question that remains is how is this new paradigm best applied in the clinic? Key
issues include how patients in clinical remission should bemonitored, and what a clini-
cian should do when active inflammation is encountered on surveillance endoscopy.
Assessment of the mucosa and success at achieving healing requires interval
evaluation of the bowel, and current evidence further favors histology. This approach
implies the need for repeat endoscopic assessment, which has limitations in cost and
patient acceptance. Although endoscopy for dysplasia detection is effective and
continually improving with technology, the invasiveness, lack of resources, and, prob-
ably, cost-ineffectiveness precludes the performance of endoscopy (and biopsies)
every 3 to 6 months from the time of diagnosis. Therefore, surrogate markers of
mucosal healing, including blood-based and stool-based biomarkers and noninvasive,
nonradiation imaging techniques will remain a focus of continued investigation. For
example, the use of neutrophil-derived fecal markers, including calprotectin and lacto-
ferrin, has been positively correlated with endoscopic and histologic activity.43 The key
clinical consideration is that baseline determinations of these noninvasive assess-
ments must be obtained and correlated with endoscopic findings to provide meaning
to changes over time. In addition, the timing intervals for monitoring remain unclear.
Extrapolating from primary clinical trials evaluating mucosal healing, it is known that
in the case of anti–TNF-a agents by week 6 to 8, mucosal healing rates (Mayo endo-
scopic subscore or equivalent score 0–1) were 42.3% to 62.0% in UC,41,44–46 and
by weeks 10 to 12 were 27% to 31% in Crohn’s disease.47,48 An important point is
that in all of the UC trials, the maintenance rates of mucosal healing were all similar
to or lower than that at the induction time point, suggesting that surrogate evaluation
as frequently as every 8 weeks could indicate a change in mucosal healing.
For now, the most frequent question that arises is related to the performance of
routine (guideline-based) surveillance in the asymptomatic patient and the unantici-
pated inflammation. First, it is important to determine whether the findings are due
to an alternative cause such as infection with Clostridium difficile or cytomegalovirus.
In the setting of true active inflammation, the clinician should reassess the patient’s
symptoms (or lack thereof) and adherence to the existing regimen of therapy, as often
patients will self-discontinue or self-reduce a dose without a discussion with their pro-
vider; this is especially true when the patient is feeling well. When patients are truly
compliant with therapy and in clinical remission but have endoscopic inflammation,
it is reasonable to optimize the existing therapies as an initial step. This approach
may include maximizing therapy within the same class of therapies, which can be
achieved via therapeutic drug monitoring with thiopurine metabolites or serum mono-
clonal antibody levels, in addition to determination of antidrug antibodies. After any in-
terval change in therapy, reassessment of the mucosa to determine success is
reasonable. The timing of such reassessment is based on the likelihood that a thera-
peutic adjustment does affect change, which and may occur after 3 to 6 months.
Endoscopic or acceptable surrogates may be used to evaluate change. Only after
optimization of current therapies has been attempted would it be appropriate to
discuss the relative benefits and risks of stepping up to the next class of therapy. Pa-
tient acceptance of this approach is critical to implementation (Box 3).
A similar approach might be used for patients who desire an alternative or comple-
mentary therapy for their IBD. In such unproven therapies, a negotiated trial of the
Box 3
Optimization options for the patient who is not healed (without needing to change class of
therapy)
Assess Compliance with Current Regimen
5-ASA
Dose or delivery response
Increase dose
Add rectal therapy
Thiopurine
Assess metabolite profile
Dose increase
If shunting, consider allopurinol
Anti-TNF: immunogenicity is a risk
Dose increase
Consider levels and antibody assessment
Switch within class
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very helpful for the patient, the clinician, and the so-called therapeutic alliance be-
tween them. When such therapeutic trials succeed (or not), an informed discussion
about making treatment changes can occur.
FUTURE APPROACHES
Although the incidence of CRC in IBD appears to be decreasing, the mechanism for
this decline remains unclear. Significant gaps in the literature remain regarding how
clinicians may enhance primary and secondary prevention of colitis-associated
dysplasia. There currently is no standard definition of mucosal healing. While clinical
trial literature has elected to use any one of the many endoscopic scoring systems, ev-
idence points to persistent histologic inflammation in the setting of endoscopic quies-
cence. It is theorized that persistent histologic inflammation will increase the risk of
CRC, but aggressive efforts to change medical therapy in pursuit of this end point
carry both long-term and short-term risks of side effects for an unproven benefit. A
unified definition of inflammation control (endoscopic, histologic, radiologic, or other)
would allow for better comparison of the efficacy of medical therapy for the induction
and maintenance of mucosal healing, in addition to the disease-modifying long-term
outcomes, including the risk of colitis-associated CRC.
There is limited to no information about the success of a combination random and
targeted surveillance approach to detection of dysplasia, and little has been written
about the interval improvement in inflammation control that may also improve detec-
tion and prevention. Finally, given the logistical challenges and inherent flaws of retro-
spective case-control and cohort studies, coupled with the significant number of
patients and duration of follow-ups required for prospective CRC prevention studies,
it may be best to continue to promote investigation in patient adherence to therapy
and compliance to recommended guidelines for surveillance.
In the absence of direct evidence of cancer benefit, the movement of research in
IBD toward control of mucosal inflammation as a disease-modifying end point seems
Chapman & Rubin362sufficient to continue to pursue improved disease control and, secondarily, to antici-
pate reduced neoplasia as a downstream result.
SUMMARY
Medical therapy, as in the case of 5-ASA, may have mechanistic plausibility for direct
antineoplastic properties, but others, such as thiopurines, do not, suggesting that
there is a primary chemopreventive benefit derived from the ability to achieve endo-
scopic and histologic healing. Mucosal healing induced by medical therapy may
also provide a secondary preventive benefit by allowing improved endoscopic and
histologic detection and differentiation between reactive epithelial changes and
dysplasia.
Of the many risk factors for the development of colitis-associated CRC, the only
modifiable one for a treating physician is the presence and severity of chronic inflam-
mation. Over the past 20 years, significant progress has been made with the use of
agents capable of mucosal healing, and during this time the risk of CRC in IBD patients
has declined. Although the mechanism of the declining risk of CRC in IBD remains un-
clear, the likely determinants are a combination of primary prevention from improved
medical therapies able to induce mucosal healing, and secondary prevention from
improved surveillance endoscopy technologies.
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